Appeal 2007-1070
Application 09/467,901
(b) mixing the mixture I with a carrier to which is
bound (iii) an IgE receptor, wherein said IgE receptor is CD23
(FсεRII) and/or FсεRI, to form a mixture II comprising carrier-
bound IgE-containing complexes,
(c) separating the carrier-bound IgE-containing
complexes from the mixture II,
(d) adding a label compound to the carrier-bound IgE-
containing complexes resulting from the separation step (c) to
form a mixture II’,
(e) separating the labeled carrier-bound IgE-
containing complexes from the mixture II’, and
(f) determining the amount of the carrier-bound IgE-
containing complexes formed by detecting the label present in
the carrier-bound IgE-containing complexes,
wherein the label compound is associated with the ligand or the
IgE antibody.
23. A method of detecting and/or quantifying
physiologically active forms of an IgE antibody specific to a
ligand in the form of an antigen, an antibody, or a hapten in
liquid sample suspected to contain the IgE antibody by
simulating in vivo interactions between the IgE antibody, the
IgE antibody’s ligand and the IgE antibody’s receptor,
comprising the steps of:
(a) contacting (i) the sample with (ii) a free dissolved
ligand in the form of an antigen, an antibody, or a hapten to
form a mixture I comprising complexes that comprise the IgE
antibody and the ligand (IgE-containing complexes),
(b) mixing the mixture I with a carrier to which is
bound (iii) an IgE receptor, wherein said IgE receptor is CD23
(FсεRII) and/or FсεRI, to form a mixture II comprising carrier-
bound IgE-containing complexes, and wherein the complexes
that comprise the IgE antibody and the ligand are formed prior
4
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: September 9, 2013